Our mission is to develop herpesvirus-based animal vaccines to protect against infectious diseases. We are using recombinant viral vector technology to develop new vaccines for use in animals to tackle diseases falling into two broad categories: - Zoonotic diseases, such as COVID-19, Ebola and Lassa fever, which jump from animals to humans; - Diseases such as bovine tuberculosis, porcine reproductive & respiratory syndrome and African Swine Fever which have a high impact on production of economically important livestock. Most emerging infections, especially those with high pandemic potential in humans, emerge from domestic and wildlife animal populations. Due to the earlier ability to test animal vaccines in their intended host, and the relative speed at which animal compared to human vaccines are approved for use, vaccination of animals rather than humans is becoming accepted as an approach to protect humans against some emerging zoonotic pathogens. Our business model is to develop vaccine candidates to Proof of Concept with commercial exploitation delivered through license agreements with vaccine manufacturing companies.